Cargando…

A Novel Phenotype of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity The High-Risk Patient

BACKGROUND: Some nonsteroidal anti-inflammatory drug (NSAID)-hypersensitive patients develop adverse reactions when challenged with weak cyclooxygenase 1 (COX-1) inhibitors. OBJECTIVES: To investigate the prevalence and clinical features of this high-risk population. MATERIALS AND METHODS: Patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez-Borges, Mario, Capriles-Hulett, Arnaldo, Caballero-Fonseca, Fernan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3650990/
https://www.ncbi.nlm.nih.gov/pubmed/23282933
http://dx.doi.org/10.1097/WOX.0b013e3181971b89
_version_ 1782269144218992640
author Sánchez-Borges, Mario
Capriles-Hulett, Arnaldo
Caballero-Fonseca, Fernan
author_facet Sánchez-Borges, Mario
Capriles-Hulett, Arnaldo
Caballero-Fonseca, Fernan
author_sort Sánchez-Borges, Mario
collection PubMed
description BACKGROUND: Some nonsteroidal anti-inflammatory drug (NSAID)-hypersensitive patients develop adverse reactions when challenged with weak cyclooxygenase 1 (COX-1) inhibitors. OBJECTIVES: To investigate the prevalence and clinical features of this high-risk population. MATERIALS AND METHODS: Patients from 2 outpatient allergy clinics consulting between October 2005 and October 2007 because of adverse reactions to classic NSAIDs were submitted to confirmatory double-blind oral challenges with the suspected NSAID and with acetaminophen, preferential and/or specific COX-2 inhibitors. Patients were then classified as low-risk and high-risk groups according to the results of provocation tests. RESULTS: Three hundred three patients were studied: 179 (59.0%) were tolerant to acetaminophen and the selective COX-2 inhibitors (low-risk group), whereas 124 (40.9%) developed reactions to at least one of the ''low COX-1 inhibitors'' (high-risk group). No distinctive demographic or clinical characteristics were present when both groups of patients were compared. CONCLUSIONS: A large proportion of patients sensitive to classic NSAIDs cannot tolerate the weak COX-1 inhibitors. Oral challenges should be performed by trained specialists to advise these patients about the use of NSAIDs.
format Online
Article
Text
id pubmed-3650990
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher World Allergy Organization
record_format MEDLINE/PubMed
spelling pubmed-36509902013-07-12 A Novel Phenotype of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity The High-Risk Patient Sánchez-Borges, Mario Capriles-Hulett, Arnaldo Caballero-Fonseca, Fernan World Allergy Organ J Original Research BACKGROUND: Some nonsteroidal anti-inflammatory drug (NSAID)-hypersensitive patients develop adverse reactions when challenged with weak cyclooxygenase 1 (COX-1) inhibitors. OBJECTIVES: To investigate the prevalence and clinical features of this high-risk population. MATERIALS AND METHODS: Patients from 2 outpatient allergy clinics consulting between October 2005 and October 2007 because of adverse reactions to classic NSAIDs were submitted to confirmatory double-blind oral challenges with the suspected NSAID and with acetaminophen, preferential and/or specific COX-2 inhibitors. Patients were then classified as low-risk and high-risk groups according to the results of provocation tests. RESULTS: Three hundred three patients were studied: 179 (59.0%) were tolerant to acetaminophen and the selective COX-2 inhibitors (low-risk group), whereas 124 (40.9%) developed reactions to at least one of the ''low COX-1 inhibitors'' (high-risk group). No distinctive demographic or clinical characteristics were present when both groups of patients were compared. CONCLUSIONS: A large proportion of patients sensitive to classic NSAIDs cannot tolerate the weak COX-1 inhibitors. Oral challenges should be performed by trained specialists to advise these patients about the use of NSAIDs. World Allergy Organization 2009-02-15 /pmc/articles/PMC3650990/ /pubmed/23282933 http://dx.doi.org/10.1097/WOX.0b013e3181971b89 Text en Copyright ©2009 World Allergy Organization; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Sánchez-Borges, Mario
Capriles-Hulett, Arnaldo
Caballero-Fonseca, Fernan
A Novel Phenotype of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity The High-Risk Patient
title A Novel Phenotype of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity The High-Risk Patient
title_full A Novel Phenotype of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity The High-Risk Patient
title_fullStr A Novel Phenotype of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity The High-Risk Patient
title_full_unstemmed A Novel Phenotype of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity The High-Risk Patient
title_short A Novel Phenotype of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity The High-Risk Patient
title_sort novel phenotype of nonsteroidal anti-inflammatory drug hypersensitivity the high-risk patient
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3650990/
https://www.ncbi.nlm.nih.gov/pubmed/23282933
http://dx.doi.org/10.1097/WOX.0b013e3181971b89
work_keys_str_mv AT sanchezborgesmario anovelphenotypeofnonsteroidalantiinflammatorydrughypersensitivitythehighriskpatient
AT caprileshulettarnaldo anovelphenotypeofnonsteroidalantiinflammatorydrughypersensitivitythehighriskpatient
AT caballerofonsecafernan anovelphenotypeofnonsteroidalantiinflammatorydrughypersensitivitythehighriskpatient
AT sanchezborgesmario novelphenotypeofnonsteroidalantiinflammatorydrughypersensitivitythehighriskpatient
AT caprileshulettarnaldo novelphenotypeofnonsteroidalantiinflammatorydrughypersensitivitythehighriskpatient
AT caballerofonsecafernan novelphenotypeofnonsteroidalantiinflammatorydrughypersensitivitythehighriskpatient